文献速递神经肿瘤

胶质母细胞瘤切除术后治疗可及性预测:基于区域剥夺指数(ADI)的社区层面劣势分析

Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).
PubMed 文献 · J Neurooncol · 2022-05-03

该5年回顾性研究纳入434例胶质母细胞瘤患者,按区域剥夺指数(ADI)分为更劣势组(ADI 34-100%,n=244)与较少劣势组(ADI 0-33%)。校正后,更劣势组接受全切、化疗、放疗、放化疗、肿瘤电场治疗及临床试验的比值均降低,但生存期与术后卡氏功能状态评分无差异。

要点

  • 更劣势组(ADI 34-100%)接受全切的校正比值比为0.43(95%CI 0.27-0.68,p<0.001)。
  • 更劣势组接受化疗、放疗、放化疗、肿瘤电场治疗及临床试验的校正比值比均降低。
  • 两组生存期及术后卡氏功能状态评分未见差异。

核心结论

  • 更劣势的胶质母细胞瘤患者接受全切的比值降低,接受放化疗等标准治疗及参与临床试验的比值也降低。
  • 需要更多研究识别可改变的社會决定因素(SDoH)障碍以改善劣势患者术后治疗。

研究设计与样本

  • 2012至2017年对罗德岛医院与梅奥诊所数据库进行的5年回顾性研究。
  • 纳入≥18岁胶质母细胞瘤患者434例,将地址匹配至ADI百分位并分为更劣势组(ADI 34-100%,n=244)与较少劣势组(ADI 0-33%)。
  • 采用校正多变量回归比较两组结局。

主要发现

  • 434例中92.9%有保险,56.2%为更劣势(n=244),更劣势组平均年龄62岁。
  • 校正后更劣势组接受全切的aOR为0.43(95%CI 0.27-0.68;p<0.001)。
  • 更劣势组接受化疗的aOR为0.51(95%CI 0.26-0.98)。
  • 更劣势组接受放疗的aOR为0.39(95%CI 0.20-0.77)、放化疗的aOR为0.42(95%CI 0.23-0.77)、肿瘤电场治疗的aOR为0.39(95%CI 0.16-0.93)、临床试验参与的aOR为0.47(95%CI 0.25-0.91)。
  • 两组生存期长度或术后卡氏功能状态评分未见差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Social determinants of health (SDoH)-socioeconomic and environmental factors-impact outcomes. The Area Deprivation Index (ADI), a composite of seventeen SDoH factors, has been correlated with poorer outcomes. We aimed to compare outcomes and treatment access for glioblastoma, a universally fatal malignant brain tumor, in patients more (ADI 34-100%) versus less disadvantaged (ADI 0-33%). METHODS: A 5-year retrospective study of Rhode Island Hospital and Mayo Clinic databases was conducted from 2012 to 2017 for patients ≥ 18 years with glioblastoma. Patient addresses were matched to ADI percentiles and grouped into more (top 66% ADI) and less disadvantaged. Adjusted multivariable regressions were used to compare outcomes between groups. RESULTS: A total of 434 patients met inclusion; 92.9% were insured, 56.2% were more disadvantaged (n = 244), and the more disadvantaged cohort was younger on average (62 years). After adjustment, the more disadvantaged group had decreased odds of receiving gross total resection (adjusted odds ratio (aOR) 0.43, 95% CI [0.27-0.68]; p < 0.001). This cohort also had decreased odds of undergoing chemotherapy (aOR 0.51[0.26-0.98]), radiation (aOR 0.39[0.20-0.77]), chemoradiation (aOR 0.42[0.23-0.77]), tumor-treating fields (aOR 0.39[0.16-0.93]), and clinical trial participation (aOR 0.47[0.25-0.91]). No differences in length of survival or postoperative Karnofsky Performance Status Scale were observed. CONCLUSION: More disadvantaged glioblastoma patients had decreased odds of receiving gross total resection. They also exhibited decreased odds of receiving standard of care like chemoradiation as well as participating in a clinical trial, compared to the less disadvantaged group. More research is needed to identify modifiable SDoH barriers to post-operative treatment in disadvantaged patients with glioblastoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Rivera Perla KM, Tang OY, Durfey SNM, et al. Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). J Neurooncol. 2022. PMID: 35503190. doi:10.1007/s11060-022-04020-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。